PENGARUH PEMBERIAN TELMISARTAN DAN METFORMIN TERHADAP ASAM LEMAK BEBAS PADA PASIEN SINDROM METABOLIK
| Main Author: | ADHITYA, FIRMAN |
|---|---|
| Format: | Thesis NonPeerReviewed |
| Terbitan: |
[Yogyakarta] : Universitas Gadjah Mada
, 2015
|
| Subjects: | |
| Online Access: |
https://repository.ugm.ac.id/134749/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=77831 |
Daftar Isi:
- Metabolic syndrome is a syndrome consisting of central obesity, hypertension, diabetes and dyslipidemia. Free fatty acids play an important role for the occurrence of the metabolic syndrome. Metformin lowers plasma free fatty acids by decreasing efflux of free fatty acids and improve peripheral insulin sensitivity. Telmisartan is an agonist of PPAR-Î3 and the drug is expected to improve insulin sensitivity This study aimed to determine the effects of telmisartan and metformin therapy on reducing free fatty acid levels in patients with the metabolic syndrome. This study used a before-after design. The patient is given telmisartan and metformin therapy treatment for 12 weeks. The subjects of the study in which patients with metabolic syndrome (central obesity, diabetes and hypertension). Dose of telmisartan 80 mg / day. Metformin doses starting from 500 mg / day and the maximum dose of 2 g / day. The result, there are 27 research subjects. average age of 57.5 years. There is a decrease in plasma free fatty acid levels before treatment, the average 1117.34 ± 467.5 Î1⁄4m and after therapy 892.27 ± 396.5 Î1⁄4m, p = 0.001. There were no differences in body mass index, waist circumference, systolic and diastolic blood pressure and fasting blood glucose before and after therapy. The conclusion that there is a decrease in plasma free fatty acids after administration of telmisartan and metformin in patients with metabolic syndrome.